IMR Press / CEOG / Volume 40 / Issue 2 / pii/1630388177454-1661194046

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Dihydrotestosterone may contribute to the development of migraine headaches
J.H. Check1,2,*R. Cohen2, 3
Show Less
1 Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, NJ
2 The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School at Camden, Cooper Hospital/University Medical Center, Department of Obstetrics and Gynecology Division of Reproductive Endocrinology and Infertility, Camden, NJ
3 Philadelphia College of Osteopathic Medicine, Department of Obstetrics and Gynecology, Philadelphia, PA (USA)
Clin. Exp. Obstet. Gynecol. 2013, 40(2), 217–218;
Published: 10 June 2013

Purpose: To evaluate the possibility that dihydrotestosterone (DHT) may play a role in the etiology of some people’s migraine headaches. Methods: Finasteride 5 mg daily was given to a young woman with chronic migraines. Results: The chronic migraine headaches almost completely disappeared shortly following therapy. However, symptoms returned shortly after stopping the finasteride due to dry eyes. Conclusions: DHT may be an etiologic factor in causing migraines since finasteride suppresses DHT secretion. Alternatively, the benefit could be related to some other property of finasteride possibly by increasing testosterone which may compete with estrogen at the blood vessel level.
Migraine headaches
5 alpha reductase inhibitor
Back to top